Company
Hyku
Hyku Biosciences is developing small molecule therapeutics with novel mechanisms of action to potently inactivate proteins that drive disease progression.
Also known as Hyku Biosciences, HYKU BIOSCIENCES INC.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- Burlington, MA, United States
- Legal name
- HYKU BIOSCIENCES INC.
- hykubiosciences.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
To achieve this goal, we are pioneering our proprietary Hyku platform, which identifies compounds that covalently bind non-cysteine amino acids to facilitate development of novel therapies that can address current challenges associated with many disease targets, including selectivity, druggability, and resistance.
Funding snapshot
- Total raised
- $56MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Undisclosed, $56M2023-09-19
Funding rounds
- Round, 2026
- $8.6M2026-07-30, SEC form D sold, 4 investors
- Round, 2025
- $6.6M2025-12-10, SEC form D sold, 8 investors
- Round, 2023
- $56M2023-09-19, Company stated
Loading relationship preview